Stockscreener 앱 받기
0.6976
10.13%
-0.0786
시간 외 거래:
.70
0.0024
+0.34%
전일 마감가:
$0.7762
열려 있는:
$0.771
하루 거래량:
802.46K
Relative Volume:
0.64
시가총액:
$123.35M
수익:
-
순이익/손실:
$-274.18M
주가수익비율:
-0.2752
EPS:
-2.5346
순현금흐름:
$-198.33M
1주 성능:
-8.52%
1개월 성능:
-5.28%
6개월 성능:
-94.14%
1년 성능:
-92.46%
1일 변동 폭
$0.695
$0.7792
1주일 범위
$0.695
$0.7999
52주 변동 폭
$0.6211
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
명칭
Neumora Therapeutics Inc
전화
(857) 760-0900
주소
490 ARSENAL WAY, SUITE 200, WATERTOWN
NMRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
0.6976 | 123.35M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-03-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Hold |
| 2023-10-10 | 개시 | BofA Securities | Buy |
| 2023-10-10 | 개시 | Guggenheim | Buy |
| 2023-10-10 | 개시 | JP Morgan | Overweight |
| 2023-10-10 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-10 | 개시 | Stifel | Buy |
| 2023-10-10 | 개시 | William Blair | Outperform |
모두보기
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
Schonfeld Strategic Advisors LLC Increases Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday - MarketBeat
Invesco Ltd. Raises Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - NatLawReview.com
Nothing is Better Than Neumora Therapeutics Inc (NMRA) stock at the moment - Sete News
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Position Increased by Wells Fargo & Company MN - Defense World
Should investors be concerned about Neumora Therapeutics Inc (NMRA)? - uspostnews.com
NMRA stock rated an Underperform by BofA Securities - knoxdaily.com
Wainwright maintains $18 target on Neumora Therapeutics stock By Investing.com - Investing.com Canada
Neumora Therapeutics (NASDAQ:NMRA) versus Big Cypress Acquisition (OTCMKTS:BCYP) Head to Head Comparison - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky About Pending Class ActionNMRA - ACCESS Newswire
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by Capital International Investors - MarketBeat
It is Poised to be a Bull Market for Neumora Therapeutics Inc (NMRA) - Sete News
NMRA Stock Sees Surge of Approximately 8.37% in Last Five Days - knoxdaily.com
NMRA’s valuation metrics: A comprehensive analysis - uspostnews.com
Former Neumora CEO to lead Galapagos spinout - BioPharma Dive
Franklin Resources Inc. Sells 44,345 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Consensus PT from Analysts - MarketBeat
Alliancebernstein L.P. Sells 22,930 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Receives Buy Rating from Needham & Company LLC - MarketBeat
Vanguard Group Inc. Purchases 195,142 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of “Hold” by Analysts - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Neumora Therapeutics (NASDAQ:NMRA) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc.: Strategic Advancements and Optimism Drive Buy Rating - TipRanks
Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Neumora Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion. - TradingView
Neumora Therapeutics, Inc. (NASDAQ: NMRA) Investor Alert: Deadline in Lawsuit on April 7, 2025 - openPR.com
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky - GlobeNewswire
Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky about Pending Class ActionNMRA - ACCESS Newswire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your RightsNMRA - PR Newswire
NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, - GlobeNewswire
NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. - Bluefield Daily Telegraph
NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Fir - TradingView
NMRA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of - GlobeNewswire
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - Morningstar
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
NMRA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit - The Malaysian Reserve
NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm - PR Newswire
Shareholders That Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky About Pending Class ActionNMRA - ACCESS Newswire
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora ... - Bluefield Daily Telegraph
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora Therapeutics, Inc.(NMRA) - GlobeNewswire
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Neumora Therapeutics, Inc. to Contact the Firm Today! - markets.businessinsider.com
Neumora Therapeutics' (NMRA) "Underperform" Rating Reaffirmed at Bank of America - MarketBeat
Neumora Therapeutics Inc (NMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Neumora Therapeutics Inc 주식 (NMRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
13,871 |
23,468 |
7,405,004 |
| Milligan Michael Lee | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
1,978 |
3,351 |
22,470 |
| Aurora Daljit Singh | Chief Strategy Officer |
Feb 18 '25 |
Sale |
1.68 |
8,565 |
14,347 |
88,935 |
| Lenz Robert A. | Head of R&D |
Feb 18 '25 |
Sale |
1.67 |
5,614 |
9,383 |
309,092 |
| Pinto Joshua | President |
Feb 18 '25 |
Sale |
1.67 |
8,048 |
13,477 |
76,952 |
0.39%
3.66%
자본화:
|
볼륨(24시간):